

# A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus

Botfield, Hannah F; Uldall, Maria S; Westgate, Connor S J; Mitchell, James L; Hagen, Snorre M; Gonzalez, Ana Maria; Hodson, David J; Jensen, Rigmor H; Sinclair, Alexandra J

DOI:

[10.1126/scitranslmed.aan0972](https://doi.org/10.1126/scitranslmed.aan0972)

License:

Other (please specify with Rights Statement)

*Document Version*

Peer reviewed version

*Citation for published version (Harvard):*

Botfield, HF, Uldall, MS, Westgate, CSJ, Mitchell, JL, Hagen, SM, Gonzalez, AM, Hodson, DJ, Jensen, RH & Sinclair, AJ 2017, 'A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus', *Science Translational Medicine*, vol. 9, no. 404, ean0972. <https://doi.org/10.1126/scitranslmed.aan0972>

[Link to publication on Research at Birmingham portal](#)

## **Publisher Rights Statement:**

This is the author's version of the work. It is posted here by permission of the AAAS for personal use, not for redistribution. The definitive version was published in *Science Translational Medicine*, Volume 9 on 23rd August 2017, DOI: 10.1126/scitranslmed.aan0972

## **General rights**

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

## **Take down policy**

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

## 1 **Supplementary Information**

2

3

## 4 **Supplementary Materials and Methods**

### 5 **Reagents**

6 | Exendin-4 (GLP-1R agonist), exendin-9-39 (GLP-1R antagonist), ouabain (specific Na<sup>+</sup> K<sup>+</sup>  
7 | ATPase inhibitor), 3-Isobutyl-1-methylxanthine (IBMX; phosphodiesterase inhibitor) and  
8 | Forskolin (adenylate cyclase activator) were purchased from Sigma-Aldrich. For the in vivo  
9 | studies exendin 9-39 was purchased from Cohesion Biosciences (CCP1199) and Abcam  
10 | (ab141101). Fluorescently tagged exendin-4 (FLEX) was purchased from AnaSpec (AS-  
11 | 63899). The myristoylated PKA inhibitor (PKI)-(14-22)-amide was purchased from Merck  
12 | Chemicals. Mouse monoclonal antibody against human GLP-1R protein was purchased from  
13 | the Developmental Studies Hybridoma Bank (Iowa; Mab 3F52, deposited by Knudsen, L.B.).  
14 | Primary antibodies for choroid plexus epithelial (CPE) cell characterization included antibodies  
15 | against transthyretin (TTR; sheep, ab9015, Abcam), Na<sup>+</sup> K<sup>+</sup> ATPase (rabbit, ab76020, Abcam;  
16 | mouse, 05-369, Millipore), zona occludens-1 (ZO-1; rabbit, 61-7300, Life Technologies),  
17 | aquaporin 1 (AQP1; rabbit, AB3065, Abcam; rabbit, AB2219, Millipore) and β-actin (mouse,  
18 | A5441, Sigma Aldrich). For immunohistochemistry, the Alexa Fluor<sup>®</sup> labelled secondary  
19 | antibodies were purchased from Life Technologies and for western blot, HRP-conjugated  
20 | secondary antibodies were bought from Cell Signaling Technology. Cell culture reagents were  
21 | from Life Technologies or Sigma-Aldrich and unless specified all other chemicals were  
22 | purchased from Sigma-Aldrich. For surgical procedures the midazolam was purchased from B.  
23 | Braun and the fluanisone and fentanylcitrate from the Danish pharmacy supply.

24

### 25 **In vitro experiments**

26 **Whole Choroid plexus.** The choroid plexus from the lateral ventricles were dissected and  
27 placed in artificial CSF (aCSF; 118mM NaCl, 22mM NaHCO<sub>3</sub>, 1.45mM K<sub>2</sub>HPO<sub>4</sub>, 1mM  
28 MgSO<sub>4</sub>, 1mM CaCl<sub>2</sub> and 10mM glucose). To ~~evaluate the effects of exendin-4 on~~demonstrate  
29 the presence of the GLP-1R ~~localisation within the cell in the choroid plexus~~, whole choroid  
30 plexus was incubated with aCSF containing (a) 1µM FLEX for 15 and 30 minutes or (b) 1µM  
31 exendin 9-39 for 10 minutes followed by 1µM FLEX for 30 minutes. 100nM Exendin 9-39 for  
32 15 minutes followed by 100nM exendin-4 for 30 minutes or 100nM exendin-4 only for 15 and  
33 30 minutes. Whole choroid plexus was then fixed and visualized under a Zeiss LSM 510 UV-  
34 confocal microscope (Carl Zeiss)~~stained following the protocol described below~~. To determine  
35 the effects of exendin-4 on GLP-1R mRNA expression the choroid plexus was incubated with  
36 aCSF containing 100nM exendin-4 for 3 and 6 hours, immediately frozen in liquid nitrogen  
37 and stored at -80°C.

38  
39 **Primary CPe cell culture.** Choroid plexus tissue from lateral and fourth ventricles were  
40 dissected and incubated with 0.25% trypsin solution for 2.5 hours at 4°C followed by 30  
41 minutes at 37°C. Trypsin digestion was stopped by the addition of newborn calf serum and the  
42 cell suspension was centrifuged at 20g for 10 minutes. Cells were resuspended in DMEM/F12  
43 supplemented with 10% FBS, 1% penicillin/streptomycin, 4mM L-glutamine, 200ng/ml  
44 hydrocortisone, 5ng/ml sodium selenite and 10ng/ml EGF. 20µM cytosine arabinoside was  
45 used for the first 4 days in culture to limit the growth of fibroblasts (53). Initially the cells were  
46 seeded onto a laminin coated 6 well plate and allowed to grow for 2 days before being  
47 transferred to laminin coated 96 well plates or 12 well inserts (Greiner Bio-One Ltd). On day 4  
48 the media was replaced with DMEM/F12 supplemented with 10% FBS and 1%  
49 penicillin/streptomycin and changed every 2-3 days. After reaching confluency, CPe cells were  
50 serum deprived for 3 days prior to the beginning of the studies (between days 10-14).

51

52 **Immunofluorescent staining.** For staining of rat brain tissue sections, rats were euthanized  
53 with rising CO<sub>2</sub> and immediately perfused transcardially with 10mM PBS, pH 7.4 (PBS)  
54 followed by 4% paraformaldehyde (PFA; Alfa Aesar) in PBS. Brains were postfixed overnight  
55 at 4°C, cryoprotected by sequential immersion in 10%, 20% and 30% sucrose in PBS at 4°C,  
56 embedded in OCT (Fisher Scientific), and 15-µm-thick coronal sections cut on a cryostat  
57 (Bright Instruments), mounted on charged microscope slides and stored at -20°C until use.  
58 Sections were first washed in PBST (PBS containing 0.3% Tween20), blocked in PBST  
59 containing 2% bovine serum albumin (BSA) and 15% normal goat serum (NGS) for 20  
60 minutes at room temperature, and then incubated with the primary antibody (PBST with 2%  
61 BSA) at 4°C overnight. After washing in PBST, sections were incubated for 1 hour at room  
62 temperature in the dark with the appropriate Alexa Fluor 488 labelled secondary antibody  
63 diluted in PBST containing 2% BSA and 1.5% NGS. Finally, sections were washed in PBST  
64 before mounting in Vectashield containing the nuclear stain DAPI (Vector Laboratories).

65 For fluorescence labelling of CPe cells, samples were first fixed in PBS containing 2%  
66 PFA and 2% glucose for 20 minutes at room temperature, washed in PBS and then  
67 permeabilized with methanol for 6 minutes at room temperature. The cells were stained using  
68 the same technique described above except that PBST was substituted with PBS.

69 Stained cells and sections were viewed under a Zeiss LSM 510 UV-confocal  
70 microscope (Carl Zeiss) and multiple Z-stack images were taken.

71

72 **Immunoperoxidase staining.** For staining of paraffin-embedded human choroid plexus, the  
73 sections were dewaxed and dehydrated to distilled water. Sections were treated for 30 minutes  
74 in Tris-EDTA buffer (pH 9.0) at 95°C in a waterbath for antigen retrieval. The sections were  
75 then cooled in PBST before incubation with 1% H<sub>2</sub>O<sub>2</sub> (70% methanol in PBS) for 30 minutes

76 to inhibit endogenous peroxidase. Sections were washed in PBST, blocked in PBST containing  
77 2% BSA and 15% normal serum for 1 hour at room temperature, and then incubated in primary  
78 antibody solution at 4°C overnight. Sections were again washed in PBST before incubation in  
79 biotinylated secondary antibody solution (Vector Laboratories) for 30 minutes at room  
80 temperature. Sections were washed in PBST and then incubated for 30 minutes at room  
81 temperature in Avidin/Biotin Complex (ABC; Vectastain Elite ABC kit, Vector Laboratories)  
82 following the manufacturer's instructions. After rinsing in PBST, sections were treated with  
83 3'3 diaminobenzidine (DAB) substrate (Vector Laboratories), washed in distilled water,  
84 counterstained with haematoxylin, washed in running water before dehydration, cleared in  
85 xylene and mounted in Vectamount medium (Vector Laboratories).

86

87 **Quantitative polymerase chain reaction (qPCR).** For qPCR studies the choroid plexus was  
88 dissected, immediately frozen in liquid nitrogen and stored at -80°C. Primary cultures of CPe  
89 cells were grown on 12 well inserts until confluency. Total RNA was extracted using the  
90 GenElute mammalian total RNA extraction kit and carried out according to the manufacturer's  
91 instructions. RNA was reverse transcribed to complementary DNA (cDNA) using a high  
92 capacity reverse transcription kit (Life Technologies) or iScript cDNA synthesis kit (Biorad)  
93 according to the manufacturer's protocol. Taqman Gene Expression Assays (Life  
94 Technologies) were used to assess the expression of GLP-1R (assay number Rn00562406\_m1  
95 and Hs00157705\_m1), Na<sup>+</sup> K<sup>+</sup> ATPase (assay number Rn01533986\_m1), AQP1 (assay  
96 number Rn00562834\_m1) and NHE1 (assay number Rn00561924\_m1). The 18S ribosomal  
97 subunit was used as an endogenous reference (4319413E) and samples were run in triplicate.  
98 The cycle number at which the particular sample crossed that threshold (Ct) was used to  
99 determine the levels of gene expression and  $\Delta$ Ct was calculated as the difference between the  
100 Ct (gene of interest) and the Ct (endogenous reference).

101  
102 **Western blot.** The choroid plexus was dissected, immediately frozen in liquid nitrogen and  
103 stored at -80°C. Tissues were homogenised in ice cold RIPA lysis buffer and centrifuged at  
104 13,000g to remove cell debris. Tissue lysates (10µg protein) were separated on a 4-12% tris-  
105 glycine gel. The proteins were transferred onto a polyvinylidene difluoride membrane and  
106 subsequently blocked with 5% skimmed milk powder in TBST (TBS pH 7.4 with 0.5%  
107 Tween20) for 1 hour at room temperature before incubation with the primary antibody diluted  
108 in milk/TBST overnight at 4°C. After washing in TBST the membranes were incubated with  
109 HRP-conjugated secondary antibody diluted in milk/TBST for 1 hour at room temperature. The  
110 bands were detected using ECL reagents (Amersham) and developed onto film.

111  
112 **cAMP assay.** The effect of exendin-4 on the downstream GLP-1R signaling pathway was  
113 assessed by measuring the levels of cAMP in CPe cells using two different techniques. The  
114 first assay was the Amersham cAMP Biotrak Enzyme immunoassay System (RPN 225, GE  
115 Healthcare Life Sciences). CPe cells were grown on a 96 well plate (described previously) and,  
116 on the day of the experiment, incubated in aCSF supplemented with 1mM IBMX containing;  
117 aCSF only (n=8), 100nM exendin-4 (n=8) or 100nM Forskolin (positive control; n=5) for 30  
118 minutes at 37°C. The cells were subsequently lysed and cAMP detected according to the  
119 manufacturer's instructions. The second assay was the LANCE® (Lanthanide chelate excite)  
120 cAMP 384 kit (PerkinElmer). CPe cells were grown in flasks and then trypsinized to form a  
121 single cell suspension. The cells were incubated in stimulation buffer (PBS with 5.5mM  
122 glucose, 0.1% BSA and 0.5mM IBMX) containing; 1nM (n=5), 10nM (n=6) and 100nM  
123 exendin-4 (n=5), with and without 1µM exendin 9-39 (n=6, n=5 and n=5 respectively), and  
124 forskolin (n=6) as a positive control. cAMP was then detected according to the manufacturer's  
125 instructions.

126

127 **Na<sup>+</sup> K<sup>+</sup> ATPase activity assay.** The effect of exendin-4 on Na<sup>+</sup> K<sup>+</sup> ATPase activity in the  
128 choroid plexus was evaluated by the colorimetric measurement of phosphate released from  
129 ATP hydrolysis with the use of a phosphate assay kit (ab65622, Abcam); with Na<sup>+</sup> K<sup>+</sup> ATPase  
130 activity being defined as the portion of phosphate produced that is sensitive to ouabain. CPe  
131 cells were incubated with aCSF for 1 hour at 37<sup>0</sup>C before incubation in aCSF containing;  
132 100nM exendin-4 (n=7), 5μM PKI-16-22-amide (n=8), 100nM exendin-4 + 5μM PKI-16-22-  
133 amide (n=8); in the presence and absence of 1mM ouabain for 30 minutes at 37<sup>0</sup>C. The cells  
134 were then lysed on ice and spun at 13,000g to remove cell debris. Phosphate was measured as  
135 per the manufacturer's instructions. Briefly the reaction mix was added to the samples and  
136 incubated at room temperature for 60 minutes before the plate was read at 690nm. Na<sup>+</sup> K<sup>+</sup>  
137 ATPase activity was calculated as the difference between the amount of phosphate produced in  
138 the presence and absence of ouabain for each treatment.

139

## 140 **In vivo experiments**

141 **Epidural ICP probe implantation.** Implantation of an epidural ICP probe and its validation  
142 were recently published as a methodological work that contains all technical and surgical detail  
143 (54). The rats were anaesthetized (2.7ml/kg subcutaneous injection containing 1.25mg/ml  
144 midazolam, 2.5mg/ml fluanisone and 0.079mg/ml fentanylcitrate), placed in a stereotactic  
145 frame (David Kopf Instruments) and a 2cm-midline incision was performed on top of the skull  
146 and the bone was exposed by retracting the skin and soft tissue. A dental drill was used to make  
147 4 burr holes in the skull; one large hole was carefully drilled to expose the dura mater enabling  
148 placement of the epidural ICP probe (C313G-3UP, PlasticsOne), with the cannula cut to be  
149 level with the base of the pedestal. The other 3 smaller holes were used to fit anchoring screws  
150 to the skull. The epidural pressure bolt and the anchoring screws were placed and aligned with

151 the interior surface of the skull and secured using dental resin-cement (Clearfil SA Cement, RH  
152 Dental). The epidural ICP probe and the transducer (DTX-Plus™, Argon Medical Devices)  
153 were then connected by a polyethylene tube filled with sterile water, ensuring the absence of  
154 air bubbles. The pressure signal was visualized and recorded using Perisoft v.2.5.5 (Perimed).  
155 Correct ICP signal was confirmed by the transient elevation of ICP after jugular vein  
156 compression. When the ICP recording procedure was completed the epidural pressure cannula  
157 was closed with a bite proof cap (303DCFTX2, PlasticsOne) and the rat allowed to recover.

158         There was one modification with the epidural ICP probe implantation in the  
159 hydrocephalic rats; before the epidural pressure bolt was placed on the dura, a small hole (1mm  
160 in diameter) was made with forceps in the dura.

161

#### 162 **Intracerebroventricular (ICV) injection**

163 During the epidural ICP probe surgery, animals receiving ICV treatments also had an ICV  
164 cannula implanted at the same time. An additional burr hole was made 0.8mm posterior and  
165 1.6mm lateral to Bregma. The cannula was inserted into the left lateral ventricle, fixed with  
166 dental resin-cement and closed by a cap with a dummy cannula to maintain patency. For the  
167 ICV injection rats were anesthetized and connected to the transducer to measure ICP. Once a  
168 stable baseline had been established a 5µl Hamilton syringe connected via tubing to an internal  
169 cannula was used for the ICV injection.

170

#### 171 **Osmotic pump implantation**

172 Osmotic pumps (model 1003D, Alzet, Durect Corporation, California, USA) were prepared  
173 under sterile conditions and primed in sterile saline overnight at 37°C to allow prompt delivery  
174 after implantation. The ICV cannula (brain infusion kit 1, Alzet) was set to 4mm and attached  
175 to the pump via 5cm catheter tubing containing saline. The osmotic pump was filled with either

176 saline or 4mg/ml exendin 9-39, thus the infusion rate was 4µg/µl/hr (around 100µg per day).  
177 The fluid in the pump and the fluid in the catheter tubing were separated by an air bubble to  
178 delay the start of exendin 9-39 until implantation.

179 For implantation of the osmotic pump, the head of anaesthetized rat was fixed in a  
180 stereotactic frame, the dorsal skull was exposed and a burr hole sited in the parietal bone  
181 0.8mm posterior and 1.6mm lateral to Bregma. The ICV cannula was inserted into the left  
182 lateral ventricle and fixed in place with glue to 2 stabilising screws (PlasticsOne), and the  
183 osmotic pump was implanted subcutaneously in the neck region. The epidural ICP probe was  
184 then implanted as above.

185


#### 186 **Induction of hydrocephalus**

187 We used the kaolin model of hydrocephalus as our model of raised ICP. The rats were  
188 anaesthetized and the head fixed in a stereotactic frame with the neck flexed down in a 90  
189 degree angle to horizontal and secured in this position. A mark was made on the skin above the  
190 dorsal atlanto-occipital membrane between the skull and the first cervical spinosus. The  
191 percutaneous injection was performed using an insulin syringe with a 30 gauge needle, which  
192 was slowly advanced in a vertical direction until there was a loss of resistance and 80 µL of  
193 sterile kaolin suspension (0.250 mg/mL in Ringer's lactate solution - 1.4mM Ca<sup>2+</sup>, 4mM K<sup>+</sup>,  
194 130mM Na<sup>+</sup>, 109mM Cl<sup>-</sup>, 28mM lactate) injected gradually (8.5 µL/s). Following the injection  
195 the neck was extended, the head released from the stereotactic frame and the animal allowed to  
196 recover.

197

198 **Blood and electrolyte Measurements.** Blood and CSF pH and electrolytes were measured  
199 immediately using an ABL80 FLEX blood gas analyzer (Radiometer Medical ApS).

200



201

202

203

204

205

206

207

208

209


210

211

212

213

**Fig. S1. Characterisation of primary rat choroid plexus epithelial (CPE) cells in vivo and in vitro.** (A) The identity of CPe cells in culture was determined by immunohistochemistry using antibodies against: (1) transthyretin (TTR), a CPe cell marker; (2) Na<sup>+</sup> K<sup>+</sup> ATPase, ion pump involved in actively moving Na<sup>+</sup> out of the CPe cells and into the CSF, (3) zona occludens-1 (ZO-1), a tight junction protein; and (4) aquaporin 1 (AQP1), the most prominent water channel in the choroid plexus. TTR staining (*green*) was observed in the cytoplasm of the CPe cells; ZO-1 (*green*) was localised at the interface between the cells indicating the presence of tight junctions; Na<sup>+</sup> K<sup>+</sup> ATPase and AQP1 (*green*) were present on the apical surface of the epithelial cells indicating the polarisation of the cells in vitro and in vivo. (B) The histogram represents the fold change in *Glp-1r* mRNA from whole choroid plexus + SEM (choroid plexus n=3; CPe cells n=3), demonstrating *Glp-1r* mRNA is present in both the CPe cells and whole choroid plexus. DAPI (blue) was used as a nuclear marker, scale bar - 50µm.



214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

**Fig. S2. Suggested route for GLP-1 action at the choroid plexus. (A)** Under physiological conditions, GLP-1 is secreted by L cells in response to nutrients in the gut and then enters the bloodstream or activates the vagus nerve. Therapeutic administration of GLP-1 mimetics is via a subcutaneous injection. Once in the bloodstream, GLP-1 could bind to GLP-1 receptors (GLP-1Rs) on the basal surface of the choroid plexus epithelial (CPE) cells or could cross the blood brain barrier and enter the CSF. Alternatively, the vagus nerve could stimulate GLP-1 production at the nucleus tractus solitarius (NTS), which has fibres projecting to the hypothalamus (H) adjacent to the CSF. This allows GLP-1 secretion into the CSF, from where it can bind with GLP-1Rs on the apical surface of the CPE cells. **(B)** In the kidney proximal tubule cells, the binding of GLP-1 to its receptor stimulates the conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP) by adenylyl cyclase (AC) through  $G\alpha_s$  protein subunit. cAMP activates protein kinase A (PKA), which phosphorylates the  $Na^+ H^+$  exchanger resulting in its inhibition, thus preventing  $Na^+$  reabsorption. **(C)** We hypothesize that activation of GLP-1R on choroid plexus epithelial cells stimulates AC, which converts ATP to cAMP. cAMP subsequently activates PKA which could phosphorylate either the  $Na^+ H^+$  exchanger or the  $Na^+ K^+$  ATPase, reducing  $Na^+$  transport from blood into the CSF. This would decrease CSF production and potentially reduce ICP.